Kanser İlaç Taşıyıcıları için Polivinil Alkol (PVA)

Polyvinyl Alcohol (PVA) is a synthetic, water-soluble polymer produced through the controlled hydrolysis of polyvinyl acetate. In the context of cancer drug delivery carriers, its utility derives from the ability to precisely tune crystallinity, hydrogel mesh size, and degradation profile via two structural variables: the degree of hydrolysis (specified as the molar percentage of hydrolyzed acetate groups) and the weight-average molecular weight (M_w). Commercially available grades intended for parenteral or implantable pharmaceutical applications conform to monographs in the United States Pharmacopeia (USP 43–NF 38), European Pharmacopoeia (Ph.Eur. 10.0), and Japanese Pharmacopoeia (JP XVIII). The polymer is listed in the FDA Inactive Ingredients Guide for intravenous, intramuscular, and ophthalmic routes. A distinguishing characteristic from other hydrophilic biomaterials such as poly(ethylene glycol) (PEG) or hydroxypropyl methylcellulose (HPMC) is the stereoregularity of the vinyl backbone, which permits physical crosslinking through repeated freeze-thaw cycles without the addition of chemical crosslinkers—an advantage in reducing cytotoxic leachables during carrier fabrication. Typical residual acetyl content ranges from 0.1 mol% for fully hydrolyzed grades to 12.5 mol% for highly water-swellable partially hydrolyzed variants, directly controlling the aqueous solubility over the temperature range of 20–80 °C. Processing into microspheres, electrospun nanofibers, or injectable in situ gelling depots is accomplished using aqueous solutions, eliminating the need for organic solvents that risk denaturing peptide or protein-based antineoplastic payloads.

What Separates PVA Grades for Chemoembolization Beads from Those Suited for Nanoparticle Lyophilization?

The selection of a specific PVA grade for a cancer drug delivery system hinges on the interplay between 4% aqueous solution viscosity (measured at 20 °C per USP <911>), molecular weight distribution, and residual acetyl content. For transarterial chemoembolization beads, a high-molecular-weight grade with M_w between 125,000 g/mol and 205,000 g/mol and a degree of hydrolysis exceeding 98.0 mol% is employed. The corresponding dynamic viscosity of a 4% w/v aqueous solution typically falls within 56–72 mPa·s. Such grades exhibit a gel fraction after five freeze-thaw cycles (freezing at -20 °C for 8 h, thawing at 25 °C for 4 h) exceeding 85%, as determined gravimetrically after water extraction at 37 °C. The high crystallinity—reflected in a melting endotherm peak temperature near 228 °C by differential scanning calorimetry—imparts compressive moduli of 40–180 kPa for cryogels at 10% w/v initial polymer concentration, sufficient to withstand arterial shear stresses during catheter delivery. In contrast, for nanoparticle lyophilization and redispersion, a lower molecular weight partially hydrolyzed grade (e.g., M_w between 31,000 g/mol and 50,000 g/mol, hydrolysis 87–89 mol%) is preferred. The viscosity of a 4% solution remains below 6.0 mPa·s, enabling high-shear homogenization at 15,000–24,000 rpm (Ultra-Turrax T25, S25N-25G dispersing tool) without excessive viscous heating. The acetyl groups disrupt intermolecular hydrogen bonding, reducing the glass transition temperature to 45–55 °C and preventing irreversible nanoparticle aggregation during freeze-drying when used as a cryoprotectant at 1–3% w/v.

Evaluating Sterilization-Induced Structural Alterations in Terminal Processing

Terminal sterilization of PVA-based cancer drug carriers imposes measurable changes in molecular weight distribution and swelling kinetics, and the selection of the sterilization modality must match the grade’s thermal and radiation sensitivity. Steam sterilization at 121 °C for 20 min in an autoclave without an external pH modifier induces hydrolysis of residual acetyl groups in partially hydrolyzed grades. For a PVA with 11.2 mol% residual acetyl, autoclaving in phosphate-buffered saline at pH 7.4 reduces the acetyl content to 8.9 mol% and lowers the equilibrium swelling ratio (weight change from dry to hydrated state) from 9.3 ± 0.4 to 7.1 ± 0.3 after a single cycle. This shift accelerates the release of hydrophilic cytotoxic agents, shortening the time to 80% cumulative release from 72 h to 48 h in vitro (paddle method, 37 °C, 50 rpm). Gamma irradiation at a dose of 25 kGy (common for pharmaceutical terminal sterilization per ISO 11137-2:2013) generates hydroxyl radicals in the aqueous state, leading to simultaneous chain scission and intermolecular crosslinking. Gel permeation chromatography traces after exposure often exhibit a bimodal molecular weight distribution with a reduced number-average molecular weight (M_n decrease of 18–30% for a starting M_n of 85,000 g/mol) and a high-molecular-weight shoulder corresponding to crosslinked fractions. Dry-state PVA scaffolds irradiated under nitrogen atmosphere exhibit predominantly crosslinking, with gel content increasing to 92% from an initial 78%, whereas hydrated irradiation skews towards chain scission. For doxorubicin-loaded PVA hydrogels fabricated from fully hydrolyzed grades, ethylene oxide sterilization at 55 °C with a gas concentration of 600 mg/L for 6 h followed by aeration at 40 °C for 12 h preserves drug loading efficiency within 5% of the as-prepared value, while autoclaving causes a 23% loss due to thermal degradation of the anthracycline moiety.

While PEG-based stealth carriers dominate the clinical pipeline for liposomal doxorubicin, PVA offers a differentiated degradation and clearance profile that is advantageous for non-systemic, regionally delivered cancer treatments. PEG is excreted renally, with a molecular weight cutoff for glomerular filtration at approximately 30 kDa. PVA with M_w exceeding 70,000 g/mol is not cleared by the kidneys in its non-degraded state and must be functionalized with acid-labile or enzymatically cleavable crosslinks (e.g., hydrazone bonds, matrix metalloproteinase-sensitive peptide sequences) to enable bioelimination. In the absence of such modifications, incomplete resorption of high-molecular-weight PVA has been documented in subcutaneous implantation models at 12 months, which limits its use in systemic intravenous nanocarriers but proves acceptable for intratumoral depots and surgical site implants where mechanical integrity is required for sustained release exceeding 4 weeks. The polymer does not generate acidic autocatalytic degradation products—a significant departure from poly(lactic-co-glycolic acid) (PLGA) carriers that release lactic and glycolic acids, causing local pH values as low as 3.0–4.0 within microsphere cores and potentially denaturing pH-labile biologics. Instead, PVA hydrogels maintain a bulk pH within 6.8–7.2 throughout the release period when buffered by interstitial fluid, as confirmed by microelectrode measurements in intratumoral dialysis sampling.

Modulating Tumor Microenvironment-Triggered Release via Dynamic Covalent PVA Networks

Incorporation of phenylboronic acid-diol dynamic covalent bonds into PVA matrices exploits the elevated reactive oxygen species (ROS) and acidic pH of the tumor milieu to confer site-specific release. PVA possessing 1,2-diol and 1,3-diol sequences along the backbone reacts with benzene-1,4-diboronic acid at pH 8.5 to form boronate ester crosslinks. The resulting hydrogels exhibit a storage modulus (G') at 1 Hz and 1% strain of 3.2 kPa at pH 7.4, which drops to 0.38 kPa upon acidification to pH 6.0—typical of the peritumoral extracellular space—and further decreases to 0.11 kPa in the presence of 1 mM H₂O₂ due to oxidative cleavage of the boronate linkage. The transition enables a 6.8-fold increase in the diffusive permeability of doxorubicin over 48 h compared to non-responsive PVA-glutaraldehyde gels of equal crosslink density. Processing equipment for such carriers includes a dual-syringe mixing system with a static mixer element (length-to-diameter ratio 10:1) to combine the PVA-boronate precursor in 0.1 M sodium carbonate buffer with the drug payload prior to injection, where gelation occurs within 45–90 s at 37 °C in vivo. Published data for this specific configuration in large animal tumor models remains limited; however, subcutaneous xenograft murine studies report tumor-to-plasma doxorubicin ratios of 12.3 ± 2.1 at 24 h post-injection, compared to 2.7 ± 0.8 for free drug.

Electrospun PVA nanofiber mats loaded with paclitaxel and fabricated on a rotating drum collector (1,200 rpm) have been investigated for post-surgical local recurrence suppression in breast cancer models. A system consisting of medium-MW partially hydrolyzed PVA (M_w 85,000–124,000 g/mol, hydrolysis 87–89 mol%) dissolved with paclitaxel at 12% w/w polymer concentration in ethanol/water (1:1 v/v) is electrospun at an applied voltage of 18 kV (positive polarity), a tip-to-collector distance of 15 cm, and a feed rate of 0.8 mL/h through a 21-gauge blunt needle. The resulting fibers exhibit a mean diameter of 340 ± 50 nm (field-emission SEM, 5 kV), with paclitaxel encapsulated in the amorphous state as confirmed by the absence of characteristic melting endotherms at 213–216 °C in differential scanning calorimetry. Residual ethanol content after vacuum drying at 40 °C for 24 h must remain below 0.5% as determined by headspace gas chromatography per USP <467> Option 1. An important operational boundary during electrospinning is the relative humidity of the processing chamber: at RH values exceeding 55%, water vapor condensation on the whipping jet induces bead formation and fiber merging, reducing the specific surface area from 14.3 m²/g (BET, N₂ adsorption) to below 6.5 m²/g. The hygroscopic nature of the partially hydrolyzed grade further necessitates pre-drying of the raw powder at 80 °C under vacuum for 4 h before solution preparation, or acceptable viscosity reproducibility within ±5% cannot be maintained batch-to-batch. PVA nanofiber carriers differ from PLGA electrospun mats in that they rapidly hydrate upon contact with peritoneal fluid, transitioning to a conformal hydrogel within 2 min and releasing 60% of the loaded paclitaxel over 14 days via Fickian diffusion (exponent n = 0.43 in Korsmeyer-Peppas model), whereas PLGA fibers degrade through bulk erosion, generating a lag phase of 7 days before significant release onset. This immediate release profile is exploited when rapid tumor bed coverage is clinically desired, while avoiding the acute inflammatory response sometimes triggered by PLGA degradation products.